Improved antibiotic-impregnated catheters with extended-spectrum activity against resistant bacteria and fungi

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 935-941

  Raad, Issam ^a   Mohamed, Jamal A ^a   Reitzel, Ruth A ^a   Jiang, Ying ^a   Raad, Sammy ^a   Al Shuaibi, Munirah ^a   Chaftari, Anne Marie ^a   Hachem, Ray Y ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORHEXIDINE; MINOCYCLINE; RIFAMPICIN; SULFADIAZINE SILVER; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BIOFILM; CANDIDA ALBICANS; CANDIDA GLABRATA; CATHETER INFECTION; CENTRAL VENOUS CATHETER; ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-INFECTIVE AGENTS; BACTERIA; BIOFILMS; CANDIDA; CATHETERIZATION, CENTRAL VENOUS; CATHETERIZATION, PERIPHERAL; CATHETERS, INDWELLING; CHLORHEXIDINE; DRUG RESISTANCE, MICROBIAL; EQUIPMENT CONTAMINATION; HUMANS; MINOCYCLINE; RIFAMPIN;

EID: 84862938707     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05836-11     Document Type: Article

References (23)

1. Bassetti M, et al. 2007. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn. Microbiol. Infect. Dis. 58:325-331. (Pubitemid 47017636)
2. Blumberg HM, et al. 2001. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin. Infect. Dis. 3:177-186. (Pubitemid 32643332)
3. Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. 2009. Methicillin-resistant Staphylococcus aureus central line associated blood-stream infections in US intensive care units, 1997-2007. JAMA 301:727-736.
4. Darouiche RO, et al. 2005. Comparison of antimicrobial impregnation with tunneling of long term central venous catheters: a randomized controlled trial. Ann. Surg. 242:193-200. (Pubitemid 41033435)
5. Darouiche RO, et al. 1999. A comparison of two antimicrobial-impregnated central venous catheters. N. Engl. J. Med. 340:1-8. (Pubitemid 29024677)
6. Furuya EY, et al. 2011. Central line bundle implementation in US intensive care units and impact on bloodstream infections. PLoS One 18:e15452.
7. Gudlaugsson O, et al. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177. (Pubitemid 37372504)
8. Hanna H, et al. 2006. Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters. Antimicrob. Agents Chemother. 50:3283-3288. (Pubitemid 44527499)
9. Hanna H, et al. 2004. Long-term silicone central venous catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J. Clin. Oncol. 22:3163-3171.
10. Hidron AI, et al. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011.
11. Hockenhull JC, et al. 2009. The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: a systematic review. Crit. Care Med. 37:702-712.
12. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773-1780. (Pubitemid 34535196)
13. O'Grady NP, et al. 2011. Guidelines for the prevention of intravascular catheter-related infections. Clin. Infect. Dis. 52:e162-e193.
14. Pittet D, Tarara D, Wenzel RP. 1994. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 271:1598-1601.
15. Pronovost P, et al. 2006. An intervention to decrease catheter-related bloodstream infections in the ICU. N. Engl. J. Med. 355:2725-2732. (Pubitemid 46021509)
16. Raad I, et al. 2007. Sources and outcome of bloodstream infections in cancer patients: the role of central venous catheters. Eur. J. Clin. Microbiol. Infect. Dis. 26:549-556. (Pubitemid 47106803)
17. Raad I, Hanna H, Maki D. 2007. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect. Dis. 7:645-657. (Pubitemid 47444563)
18. Raad I, et al. 2008. Anti-adherence activity and antimicrobial durability of anti-infective-coated catheters against multidrug-resistant bacteria. J. Antimicrob. Chemother. 62:746-750.
19. Raad II, et al. 2010. The extended broad-spectrum activity of second generation minocycline and rifampin-coated catheters (M/R CVC) against bacteria and fungi, abstr K-995. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA. American Society for Microbiology, Washington, DC.
20. Raad II. 2008. Commentary: zero tolerance for catheter-related blood-stream infections: the nonnegotiable objective. Infect. Control Hosp. Epidemiol. 29:951-953.
21. Ramritu P, et al. 2008. A systematic review comparing the relative effectiveness of antimicrobial-coated catheters in intensive care units. Am. J. Infect. Control 36:104-117. (Pubitemid 351296068)
22. Richards MJ, Edwards JR, Culver DH, Gaynes RP. 1999. Nosocomial infections in medical intensive care units in the United States. Crit. Care Med. 27:887-892. (Pubitemid 29266004)
23. Rupp ME, et al. 2005. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann. Intern. Med. 143:570-580.